Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
Report

Beyond the Lab: Biomarkers Powering Tomorrow’s Therapies

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

DTR - BtL Report - Biomarkers 2025_600x300

Innovation is moving faster, budgets are tighter, and the stakes are higher. Biomarkers aren’t just part of the picture, they’re changing it. With so many tools, standards and claims, knowing what truly drives progress is a challenge.

This expert report gives you clear, practical insight into how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – and where the real opportunities are emerging.

Access the full report >>

Here’s how it helps you:

  • Reduce uncertainty with smarter dose selection and early efficacy readouts
  • Leverage multi-omics, liquid biopsy and digital tools to refine discovery strategies
  • Ensure regulatory readiness by aligning data from the very start
  • Avoid costly missteps by designing for biomarker success from discovery to diagnostics
  • Stay ahead of competitors by spotting emerging trends 
  • Access expert knowledge curated by those shaping biomarker strategy.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Featuring expert insights from:

  • Dr Cyril Clarke, VP, ICON Biotech
  • Dr Adam Savitz, Chief Medical Officer, Alto Neuroscience
  • Gayle Marshall, Biomarker Lead, Medicines Discovery Catapult
  • Dr Andrew Roche, VP, ICON Laboratory Solutions
  • Dr Jessica Baumann, Medical Director, Companion Diagnostics & Advanced Assays, Leica Biosystems

Whether you’re building biomarker strategies or solving translational roadblocks, this report shares expert guidance to help you go from discovery to application – faster, and with more clarity.

Access the full report >>

This report is sponsored by:

ICON